Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
暂无分享,去创建一个
I. Boutron | A. Hrõbjartsson | G. Grasselli | P. Ravaud | A. Chaimani | G. Rada | D. Devane | C. Schmucker | T. Evrenoglou | C. Riveros | Y. Sguassero | A. Jarde | D. Tovey | Katrin Probyn | C. H. Nejstgaard | B. Buckley | C. Ávila | P. Kapp | Mauricia Davidson | C. Graña | Gabriel Ferrand | H. Bonnet | Nicholas Henschke | R. Assi | Lina Ghosn | Sonia Menon | C. Breuer | Joerg J. Meerpohl | Thu Van Nguyen | Lina Ghosn | Rouba Assi | Theodoros Evrenoglou | Brian S Buckley | Nicholas Henschke | Katrin Probyn | Carolina Riveros | Mauricia Davidson | Carolina Graña | Hillary Bonnet | Alexander Jarde | Camila Ávila | Camilla Hansen Nejstgaard | Sonia Menon | Gabriel Ferrand | Philipp Kapp | Christine Schmucker | Yanina Sguassero | Declan Devane | Joerg J Meerpohl | Gabriel Rada | Asbjørn Hróbjartsson | Giacomo Grasselli | David Tovey | Philippe Ravaud | Anna Chaimani | Isabelle Boutron | Philipp Kapp | Yanina Sguassero | Camila Ávila
[1] G. Guyatt,et al. GRADE Guidance article 35: Update on rating imprecision for assessing contextualized certainty of evidence and making decisions. , 2022, Journal of clinical epidemiology.
[2] E. Petkova,et al. A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation* , 2022, Critical care medicine.
[3] I. Douglas,et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA) , 2022, eClinicalMedicine.
[4] Miyoung Choi,et al. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis , 2022, Emerging microbes & infections.
[5] S. Jamal,et al. Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study , 2022, The Lancet Regional Health - Americas.
[6] E. Löyttyniemi,et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM—a prospective, randomized, single-centre, open-label study , 2022, Clinical Microbiology and Infection.
[7] R. Dhond,et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial , 2022, PloS one.
[8] R. Guleria,et al. Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials. , 2022, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.
[9] P. Ravaud,et al. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group , 2022, European Respiratory Journal.
[10] Guanzhao Liang,et al. Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis , 2022, Aging.
[11] G. McComsey,et al. Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial , 2021, Open forum infectious diseases.
[12] OUP accepted manuscript , 2022, Clinical Infectious Diseases.
[13] R. León-López,et al. Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial , 2021, Antimicrobial agents and chemotherapy.
[14] E. Vicaut,et al. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial , 2021, The Lancet Rheumatology.
[15] J. Buades,et al. Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia: A Randomized, Phase III Clinical Trial (SARTRE Study) , 2021, Infectious Diseases and Therapy.
[16] K. Blyth,et al. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial* , 2021, Critical care medicine.
[17] B. Lambrecht,et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial , 2021, The Lancet Respiratory Medicine.
[18] V. Mazurov,et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study , 2021, Inflammation research : official journal of the European Histamine Research Society ... [et al.].
[19] M. Netea,et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial , 2021, Nature Medicine.
[20] I. Boutron,et al. Secondary electronic sources demonstrated very good sensitivity for identifying studies evaluating interventions for COVID-19 , 2021, Journal of Clinical Epidemiology.
[21] Peter J. Godolphin,et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. , 2021, JAMA.
[22] M. Polymeropoulos,et al. Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients’ , 2021, Cytokine.
[23] A. Verma,et al. Managing drug shortages during a pandemic: tocilizumab and COVID-19 , 2021, Canadian Medical Association Journal.
[24] Eric A. Meyerowitz,et al. EFFECT OF TOCILIZUMAB ON CARDIAC INJURY AND DYSFUNCTION IN COVID-19 , 2021, Journal of the American College of Cardiology.
[25] Steve B Jones,et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, Lancet.
[26] R. Gans,et al. Timely Administration of Tocilizumab Improves Survival of Hospitalized COVID-19 Patients , 2021, SSRN Electronic Journal.
[27] I. Boutron,et al. Day-to-day discovery of preprint–publication links , 2021, Scientometrics.
[28] B. Wiratama,et al. Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future , 2021, Journal of inflammation research.
[29] I. Boutron,et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. , 2021, The Cochrane database of systematic reviews.
[30] M. Biehl,et al. Severe covid-19 pneumonia: pathogenesis and clinical management , 2021, BMJ.
[31] Xiaojing Wang,et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial , 2021, Frontiers of Medicine.
[32] Y. Mehta,et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial , 2021, The Lancet Respiratory Medicine.
[33] G. Canonica,et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial , 2021, The Lancet Respiratory Medicine.
[34] L. Amato,et al. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.] , 2021, Recenti progressi in medicina.
[35] M. Cortón,et al. IL-6–based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts , 2021, Journal of Allergy and Clinical Immunology.
[36] I. Douglas,et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia , 2021, The New England journal of medicine.
[37] Christopher M. Horvat,et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 - Preliminary report , 2021, medRxiv.
[38] E. Vicaut,et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial , 2021, The Lancet Respiratory Medicine.
[39] Á. Avezum,et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial , 2021, BMJ.
[40] L. Fabbri,et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19 , 2021, Thorax.
[41] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .
[42] J. Casanova,et al. Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation , 2020, Med.
[43] G. Criner,et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia , 2020, The New England journal of medicine.
[44] Cameron R. Wolfe,et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.
[45] N. Koulouris,et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison , 2020, Nature Immunology.
[46] I. Boutron,et al. Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study , 2020, BMC Medicine.
[47] J. Jakobsen,et al. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project) , 2020, medRxiv.
[48] I. Tleyjeh,et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis , 2020, Clinical Microbiology and Infection.
[49] I. Boutron,et al. Interventions for the prevention and treatment of COVID-19: a living mapping of research and living network meta-analysis , 2020, Cochrane Database of Systematic Reviews.
[50] G. Mutlu,et al. IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections , 2020, Frontiers in Medicine.
[51] Eric A. Meyerowitz,et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 , 2020, The New England journal of medicine.
[52] R. Porcher,et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.
[53] M. Massari,et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.
[54] T. Hirano,et al. How COVID-19 induces cytokine storm with high mortality , 2020, Inflammation and regeneration.
[55] T. Cavero,et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study , 2020, Journal of Allergy and Clinical Immunology.
[56] Samuel M. Brown,et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study , 2020, The Lancet Rheumatology.
[57] G. Criner,et al. Preliminary predictive criteria for COVID-19 cytokine storm , 2020, Annals of the Rheumatic Diseases.
[58] Steven M. Holland,et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.
[59] I. Boutron,et al. The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic , 2020, Annals of Internal Medicine.
[60] I. González-Álvaro,et al. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial , 2020, Trials.
[61] C. Wellington,et al. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome , 2020, European Respiratory Journal.
[62] C. Wellington,et al. The Association of Inflammatory Cytokines in the Pulmonary Pathophysiology of Respiratory Failure in Critically Ill Patients With Coronavirus Disease 2019 , 2020, Critical care explorations.
[63] X. Yao,et al. Tocilizumab Ameliorates the Hypoxia in COVID-19 Moderate Patients with Bilateral Pulmonary Lesions: A Randomized, Controlled, Open-Label, Multicenter Trial , 2020 .
[64] M. Singer,et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study , 2020, The Lancet Rheumatology.
[65] C. Campochiaro,et al. The conundrum of interleukin-6 blockade in COVID-19 , 2020, The Lancet Rheumatology.
[66] G. Guyatt,et al. Drug treatments for covid-19: living systematic review and network meta-analysis , 2020, BMJ.
[67] Eric Song,et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.
[68] N. Laura,et al. Interleukin-6-based mortality risk model for hospitalised COVID-19 patients , 2020, Journal of Allergy and Clinical Immunology.
[69] R. Fumagalli,et al. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis , 2020, Journal of Infection.
[70] J. Jordán,et al. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients. , 2020, European review for medical and pharmacological sciences.
[71] M. Massari,et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.
[72] Mike Clarke,et al. A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.
[73] Jing Liu,et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial , 2020, Journal of Allergy and Clinical Immunology.
[74] B. Lipworth,et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.
[75] T. Kishimoto,et al. Historical overview of the interleukin-6 family cytokine , 2020, The Journal of experimental medicine.
[76] Y. Ho,et al. SARS-CoV-2: A Storm is Raging. , 2020, The Journal of clinical investigation.
[77] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[78] Gerta Rücker,et al. How to perform a meta-analysis with R: a practical tutorial , 2019, Evidence-Based Mental Health.
[79] Natalie S Blencowe,et al. RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.
[80] D. Altman,et al. Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews , 2018, British Medical Journal.
[81] Dimitris Mavridis,et al. Allowing for Informative Missingness in Aggregate Data Meta-Analysis with Continuous or Binary Outcomes: Extensions to Metamiss , 2018, The Stata journal.
[82] L. Scott. Tocilizumab: A Review in Rheumatoid Arthritis , 2017, Drugs.
[83] J. Stone,et al. Trial of Tocilizumab in Giant‐Cell Arteritis , 2017, The New England journal of medicine.
[84] Hossam M. Hammady,et al. Rayyan—a web and mobile app for systematic reviews , 2016, Systematic Reviews.
[85] Dimitris Mavridis,et al. Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta‐analysis , 2015, Statistics in medicine.
[86] G. Salanti,et al. Missing outcome data in meta-analysis , 2014, Evidence Based Journals.
[87] Richard D Riley,et al. Interpretation of random effects meta-analyses , 2011, BMJ : British Medical Journal.
[88] Wolfgang Viechtbauer,et al. Conducting Meta-Analyses in R with the metafor Package , 2010 .
[89] Ian R White,et al. Allowing for uncertainty due to missing data in meta‐analysis—Part 1: Two‐stage methods , 2008, Statistics in medicine.
[90] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.